Fixation control before and after treatment for neovascular age-related macular degeneration

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 7, 2011, Pages 4208-4213

  González, Esther G ^a,b,c   Tarita Nistor, Luminita ^a,b   Mandelcorn, Efrem D ^c   Mandelcorn, Mark ^c   Steinbach, Martin J ^a,b,c  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b YORK UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EYE FIXATION; FEMALE; FIXATION STABILITY; FLUORESCENCE ANGIOGRAPHY; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; PERIMETRY; PREFERRED RETINAL LOCUS; PRIORITY JOURNAL; RETINA; RETINA MACULA AGE RELATED DEGENERATION; TREATMENT OUTCOME; VISUAL ACUITY; DRUG EFFECT; PATHOPHYSIOLOGY; RETINA MACULA DEGENERATION; SUBRETINAL NEOVASCULARIZATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FEMALE; FIXATION, OCULAR; HUMANS; MACULAR DEGENERATION; MALE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 80051952155     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-7026     Document Type: Article

References (44)

1. Eye Disease Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477-485.
2. Curcio CA, Medeiros NE, Millican CL. Photoreceptor loss in agerelated macular degeneration. Invest Ophthalmol Vis Sci. 1996;37: 1236-1249.
3. Freund KB, Yannuzzi LA, Sorenson JA. Age-related macular degeneration and choroidal neovascularization. Am J Ophthalmol. 1993;115:783-791.
4. Heinen SJ, Skavenski AA. Adaptation of saccades and fixation to bilateral foveal lesions in adult monkey. Vision Res. 1992;32:365-373.
5. Crossland MD, Rubin GS. The use of an infrared eyetracker to measure fixation stability. OptomVis Sci. 2002;79:735-739.
6. Crossland MD, Sims M, Galbraith RF, Rubin GS. Evaluation of a new quantitative technique to assess the number and extent of preferred retinal loci in macular disease. Vision Res. 2004;44:1537-1546.
7. Crossland MD, Culham LE, Kabanarou SA, Rubin GS. Preferred retinal locus development in patients with macular disease. Ophthalmology. 2005;112:1579-1585.
8. Timberlake GT, Mainster MA, Peli E, Augliere RA, Essock EA, Arend LE. Reading with a macular scotoma. I. Retinal location of scotoma and fixation area. Invest Ophthalmol Vis Sci. 1986;27:1137-1147.
9. vonNoorden GK, Mackensen G. Phenomenology of eccentric fixation. Am J Ophthalmol. 1962;53:642-661.
10. White JM, Bedell HE. The oculomotor reference in humans with bilateral macula disease. Invest Ophthalmol Vis Sci. 1990;31: 1149-1161.
11. Cummings RW, Whittaker SG, Watson GR, Budd JM. Scanning characters and reading with a central scotoma. Am J Optom Physiol Opt. 1985;62:833-843.
12. Sunness JS, Applegate CA. Long-term follow-up of fixation patterns in eyes with central scotomas from geographic atrophy that is associated with age-related macular degeneration. Am J Ophthalmol. 2005;140:1085-1093.
13. Déruaz A, Whatham AR, Mermoud C, Safran AB. Reading with multiple preferred retinal loci: implications for training a more efficient reading strategy. Vision Res. 2002;42:2947-2957.
14. Duret F, Issenhuth M, Safran AB. Combined use of several preferred retinal loci in patients with macular disorders when reading single words. Vision Res. 1999;39:873-879.
15. Lei H, Schuchard RA. Using two preferred retinal loci for different lighting conditions in patients with central scotomas. Invest Ophthalmol Vis Sci. 1997;38:1812-1818.
16. Schuchard RA, Naseer S, de Castro K. Characteristics of AMD patients with low vision receiving visual rehabilitation. J Rehabil Res Dev. 1999;36:294-302.
17. Seddon JM, Chen CA. The epidemiology of age-related macular degeneration. Int Ophthalmol Clin. 2004;44:17-39.
18. Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration. Pooled findings from three continents. Ophthalmology. 2001;108:697-704.
19. Owen CG, Fletcher AE, Donoghue M, Rudnicka AR. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? Br J Ophthalmol. 2003;87:312-317.
20. Gehrs KM, Jackson JR, Brown EN, Allikmets R, Hageman GS. Complement, age-related macular degeneration and a vision of the future. Arch Ophthalmol. 2010;128:349-358.
21. Rosenfeld PJ, Brown DM, Heier JS, et al. for the MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431.
22. Brown DM, Kaiser PK, Michels MM, et al. for the ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
23. Regillo CD, Brown DM, Abraham P, et al. Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular agerelated macular degeneration: PIER Study Year 1. Am J Ophthalmol. 2008;145:239-248.
24. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology. 2006;113: 633-642.
25. Bansback N, Davis S, Brazier J. Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration. Eye. 2007;21: 1455-1463.
26. Eldaly MA, Styles C. First versus second eye intravitreal ranibizumab therapy for wet AMD. Retina. 2009;29:325-328.
27. Moutray T, Alarbi M, Mahon G, Stevenson M, Chakravarthy U. Relationships between clinical measures of visual function, fluorescein angiographic and optical coherence tomography features in patients with subfoveal choroidal neovascularisation. Br J Ophthalmol. 2008;92:361-364.
28. Moschos MM, Brouzas D, Apostolopoulos M, Koutsandrea C, Loukianou E, Moschos M. Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal-ERG and OCT study. Multifocal-ERG after use of bevacizumab in ARMD. Doc Ophthalmol. 2007;114:37-144.
29. Tarita-Nistor L, González EG, Markowitz SN, Steinbach MJ. Fixation characteristics of patients with macular degeneration recorded with the MP-1 microperimeter. Retina. 2008;28:125-133.
30. Steinman RM. Effect of target size, luminance, and color on monocular fixation. J Opt Soc Am. 1965;55:1158-1165.
31. Bartlett MS. Fitting a straight line when both variables are subject to error. Biometrics. 1949;5:207-212.
32. Tabachnick BG, Fidell LS. Using Multivariate Statistics. 5th ed. Boston: Allyn and Bacon; 2007:73.
33. Tarita-Nistor L, Brent MH, Steinbach MJ, González, EG. Fixation stability during binocular viewing in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011;52:1887-1893.
34. Timberlake GT, Wyman D, Skavenski AA, Steinman RM. The oculomotor error signal in the fovea. Vision Res. 1972;12:1059-1064.
35. Skavenski AA. Inflow as a source of extraretinal eye position information in the retina. Vision Res. 1972;12:221-229.
36. Steinbach MJ. Proprioceptive knowledge of eye position. Vision Res. 1987;27:1737-1744.
37. Costa R, Jorge R, Calucci D, Cardillo J, Melo LAJ, Scott I. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci. 2006;47:4569-4578.
38. Haegerstrom-Portnoy G. The Glenn A. Fry Award Lecture 2003: Vision in elders-summary of findings of the SKI study. Optom Vis Sci. 2003;82:87-93.
39. Sunness JS, Rubin GS, Broman A, et al. Low luminance visual dysfunction as a predictor of subsequent visual acuity loss from geographic atrophy in age-related macular degeneration. Ophthalmology. 2008;115:1480-1488.
40. Eisner A, Fleming SA, Klein ML, Mauldin WM. Sensitivities in older eyes with good acuity: eyes whose fellow eye has exudative AMD. Invest Ophthalmol Vis Sci. 1987;28:1832-1837.
41. Eisner A, Stoumbos VD, Klein ML, Fleming SA. Relations between fundus appearance and function. Eyes whose fellow eye has exudative age-related macular degeneration. Invest Ophthalmol Vis Sci. 1991;32:8-20.
42. Parravano M, Oddone F, Tedeschi M, et al. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration patients treated with ranibizumab. Retina. 2009;29:329-334.
43. Tarita-Nistor L, González EG, Mandelcorn M, Steinbach MJ. Changes in fixation stability predict visual acuity after successful macular hole surgery. Invest Ophthalmol Vis Sci. 2009;50:84-89.
44. Feigl B, Greaves A, Brown B. Functional outcomes after multiple treatments with ranibizumab in neovascular age-related macular degeneration beyond visual acuity. Clin Ophthalmol. 2007;1:167-175.